Mirae Asset Global Investments Co. Ltd. Sells 1,883 Shares of Humana Inc. (NYSE:HUM)

Mirae Asset Global Investments Co. Ltd. decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 4.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,911 shares of the insurance provider’s stock after selling 1,883 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Humana were worth $17,347,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Dorsey & Whitney Trust CO LLC increased its stake in shares of Humana by 2.6% during the third quarter. Dorsey & Whitney Trust CO LLC now owns 817 shares of the insurance provider’s stock valued at $397,000 after purchasing an additional 21 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Humana by 2.8% during the third quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock valued at $392,000 after purchasing an additional 22 shares in the last quarter. Vestcor Inc increased its stake in shares of Humana by 0.3% during the fourth quarter. Vestcor Inc now owns 8,292 shares of the insurance provider’s stock valued at $4,247,000 after purchasing an additional 22 shares in the last quarter. First Financial Corp IN increased its position in shares of Humana by 7.2% during the fourth quarter. First Financial Corp IN now owns 343 shares of the insurance provider’s stock valued at $157,000 after acquiring an additional 23 shares in the last quarter. Finally, Exencial Wealth Advisors LLC increased its position in shares of Humana by 4.1% during the fourth quarter. Exencial Wealth Advisors LLC now owns 582 shares of the insurance provider’s stock valued at $298,000 after acquiring an additional 23 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.8 %

Shares of Humana stock opened at $319.62 on Wednesday. The company’s fifty day simple moving average is $350.91 and its 200-day simple moving average is $432.70. The stock has a market capitalization of $38.56 billion, a PE ratio of 16.13, a P/E/G ratio of 1.84 and a beta of 0.45. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59.

Humana (NYSE:HUM) last issued its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). The business had revenue of $26.46 billion for the quarter, compared to analysts’ expectations of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The company’s revenue was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.62 EPS. As a group, equities analysts anticipate that Humana Inc. will post 16.02 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Friday, March 29th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date is Wednesday, March 27th. Humana’s dividend payout ratio (DPR) is 17.86%.

Insider Activity at Humana

In other news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now owns 2,578 shares in the company, valued at $946,358.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.29% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HUM. Wells Fargo & Company reduced their price target on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday. StockNews.com downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. Cantor Fitzgerald reissued a “neutral” rating and set a $391.00 price target on shares of Humana in a research report on Thursday, April 4th. Truist Financial reissued a “hold” rating and set a $550.00 price target on shares of Humana in a research report on Friday, January 19th. Finally, Argus downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $465.42.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.